AMES, Iowa, April 1, 2011 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the Company’s investigational HyperAcute® Lung cancer immunotherapy will be presented during a poster session at the American Association for Cancer Research 102nd Annual Meeting 2011 in Orlando, Florida. A summary of the poster is below.
